Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Altamira Therapeutics Ltd. (CYTOF) had Stock-Based Compensation of $0.25M for the most recently reported fiscal quarter, ending 2024-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$0.52M |
|
$0.00M |
|
$7.55M |
|
$8.07M |
|
$1.23M |
|
-- |
|
$0.52M |
|
$1.75M |
|
$6.32M |
|
$1.69M |
|
$6.32M |
|
2.67M |
|
| Cash Flow Statement Financials | |
$-3.20M |
|
$0.00M |
|
$2.51M |
|
$0.73M |
|
$0.07M |
|
$-0.67M |
|
|
Stock-Based Compensation |
$0.25M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|